Denton, Christopher P.
Wells, Athol U.
Coghlan, John G.
Article History
First Online: 15 August 2018
Change Date: 13 October 2018
Change Type: Correction
Change Details: Corrections: Table 2: the text ‘Also licensed for CTEPH; cannot be combined with a PDE5 inhibitor’ has been moved to a different row; reference for this moved statement updated.
Competing interests
: C.P.D. has received honoraria from Actelion, Bayer, Boehringer Ingelheim, GlaxoSmithKline and Roche/Genentech and consultancy fees from Actelion, Bayer, Boehringer Ingelheim, CSL Behring, GlaxoSmithKline, Inventiva, Merck-Serono, Roche/Genentech and Sanofi-Aventis. A.U.W. and J.G.C. declare no competing interests.